Agreement with Beth Israel Deaconess Medical Center Solidifies Important Technology for CND’s Syn-One Test® and Creates Opportunity for Future Innovations in the Field
Research published last month in the New England Journal of Medicine demonstrated that a focused ultrasound procedure improved motor function in patients with Parkinson’s disease.
San Diego-based Ryne Biotechnology announced last week that it has received a $4 million Clinical Stage Research Program grant from the California Institute for Regenerative Medicine (CIRM) to move RNDP-0001 into clinical testing.
Georgia Public Broadcasting featured a story this week about how the Syn-One Test helped Dr. Daniel Cobb, owner of The Neuro Center in Gainesville, Georgia, provide a diagnosis to Chris Griffin, a patient who was experiencing troubling and unexplained symptoms.
The California-based drug development company FAScinate Therapeutics, Inc. announced positive results from the first part of a Phase 2 trial of KM-819, a compound
being tested for the treatment of Parkinson’s disease.
The FDA announced that it will lift the full Clinical Hold on IkT-148009, a c-Abl tyrosine kinase inhibitor that has shown promising results at stopping the progression of Parkinson’s disease in animal models.
Ambroxol, the active ingredient in cough syrup, is set to enter a Phase 3 clinical trial early this year in patients with Parkinson’s disease.
Previous research has demonstrated that mutations in the SCNA gene, a gene responsible for the production of alpha-synuclein, are associated with an aggressive form of Parkinson’s disease.
CND Life Sciences, an innovative medical diagnostics company pioneering the detection, visualization, and quantification of protein deposition in cutaneous nerve fibers, has been awarded a $4.2 million grant from the Arizona Governor’s Office to support the creation of the world’s first digital biosignatures laboratory focused on neurodegenerative disorders.
Previous estimates of the incidence of Parkinson’s disease have varied for reasons that are not completely understood but may be attributable to the location of the study, small sample sizes, or how cases were defined.